100 related articles for article (PubMed ID: 17727556)
1. Advances in the understanding and management of myeloproliferative disorders.
Skoda R
Eur J Haematol Suppl; 2007 Oct; (68):2-4. PubMed ID: 17727556
[No Abstract] [Full Text] [Related]
2. Update on the impact of the JAK2 mutation on signalling pathways in myeloproliferative disorders.
Skoda R
Eur J Haematol Suppl; 2007 Oct; (68):5-8. PubMed ID: 17727557
[No Abstract] [Full Text] [Related]
3. Phenotype and genotype in the myeloproliferative disorders.
Spivak JL
Eur J Haematol Suppl; 2007 Oct; (68):9-12. PubMed ID: 17727558
[No Abstract] [Full Text] [Related]
4. An update of molecular pathogenesis and diagnosis of myeloproliferative disorders in the JAK2 era.
Zhang SJ; Li JY
Chin Med J (Engl); 2008 Sep; 121(18):1838-42. PubMed ID: 19080367
[No Abstract] [Full Text] [Related]
5. The JAK2V617F mutation: no impact on circulating hematopoietic progenitors in myeloproliferative disorders.
Wappl M; Jaeger E; Kusec R; Schwarzinger I; Geissler K; Oehler L
Ann Hematol; 2008 Jun; 87(6):509-11. PubMed ID: 18180923
[No Abstract] [Full Text] [Related]
6. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation.
Hussein K; Theophile K; Buhr T; Beller A; Kreipe H; Bock O
Br J Haematol; 2009 Jun; 145(5):673-5. PubMed ID: 19344408
[No Abstract] [Full Text] [Related]
7. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
Mesa RA
Curr Opin Hematol; 2008 Mar; 15(2):121-6. PubMed ID: 18300758
[TBL] [Abstract][Full Text] [Related]
8. [JAK2 mutation in myeloproliferative disorders].
Inokuchi K
Rinsho Ketsueki; 2006 Aug; 47(8):693-700. PubMed ID: 16986707
[No Abstract] [Full Text] [Related]
9. The myeloproliferative neoplasms: insights into molecular pathogenesis and changes in WHO classification and criteria for diagnosis.
Anastasi J
Hematol Oncol Clin North Am; 2009 Aug; 23(4):693-708. PubMed ID: 19577165
[TBL] [Abstract][Full Text] [Related]
10. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
Zhu P
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
[No Abstract] [Full Text] [Related]
11. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
Mercier F; Monczak Y; François M; Prchal J; Galipeau J
Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
13. JAK2V617F mutation can occur exclusively in the erythroid lineage and be absent in granulocytes and progenitor cells in classic myeloproliferative disorders.
Zehentner BK; Loken MR; Wells DA
Am J Hematol; 2006 Oct; 81(10):806-7. PubMed ID: 16886215
[No Abstract] [Full Text] [Related]
14. The recent advances in classic BCR-ABL-negative myeloproliferative disorders.
Tefferi A
Clin Adv Hematol Oncol; 2007 Feb; 5(2):113-5. PubMed ID: 17344799
[No Abstract] [Full Text] [Related]
15. Myeloproliferative neoplasms.
Kim J; Haddad RY; Atallah E
Dis Mon; 2012 Apr; 58(4):177-94. PubMed ID: 22449367
[No Abstract] [Full Text] [Related]
16. The impact of JAK2 non-receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome-negative myeloproliferative disorders.
Kannim S; Auewarakul CU
Int J Cancer; 2009 Aug; 125(4):988-90. PubMed ID: 19462461
[No Abstract] [Full Text] [Related]
17. Effect of mutation order on myeloproliferative neoplasms.
Delhommeau F
N Engl J Med; 2015 May; 372(19):1865. PubMed ID: 25946290
[No Abstract] [Full Text] [Related]
18. Effect of mutation order on myeloproliferative neoplasms.
Kent DG; Ortmann CA; Green AR
N Engl J Med; 2015 May; 372(19):1865-6. PubMed ID: 25946289
[No Abstract] [Full Text] [Related]
19. Genetics: Myeloproliferative neoplasms—order of mutations counts!
Hutchinson L
Nat Rev Clin Oncol; 2015 Apr; 12(4):187. PubMed ID: 25734632
[No Abstract] [Full Text] [Related]
20. The myeloproliferative disorders.
Campbell PJ; Green AR
N Engl J Med; 2006 Dec; 355(23):2452-66. PubMed ID: 17151367
[No Abstract] [Full Text] [Related]
[Next] [New Search]